EMA/621039/2020

European Medicines Agency decision

P/0451/2020

of 1 December 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for garadacimab (EMEA-002726-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0451/2020

of 1 December 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for garadacimab (EMEA-002726-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by CSL Behring GmbH on 29 November 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 October 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for garadacimab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for garadacimab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for garadacimab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to CSL Behring GmbH,Emil-von-Behring-Strasse 76, 35041 – Marburg, Germany.

EMA/PDCO/402432/2020
Amsterdam, 16 October 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-002726-PIP01-19

Scope of the application

Active substance(s):

Garadacimab

Condition(s):

Prevention of hereditary angioedema attacks

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

CSL Behring GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, CSL Behring GmbH submitted for agreement to the European Medicines Agency on 29 November 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 6 January 2020.

Supplementary information was provided by the applicant on 10 July 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Prevention of hereditary angioedema attacks (HAE)

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Prevention of hereditary angioedema attacks (HAE)

2.1.1. Indication(s) targeted by the PIP

Routine prevention of hereditary angioedema attacks (HAE)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality	1	**Study 1** Development of a 100mg pre-filled syringe in order to obtain an appropriate 1ml dose for use in the paediatric population from 2 to less than 12 years of age.
Non-clinical studies	0	Not applicable.
Clinical studies	3	**Study 2** Double-blind, randomized, placebo-controlled, parallel-arm, confirmatory study to evaluate the pharmacokinetics, safety and efficacy of garadacimab when administered as a prophylaxis in in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE), (CSL312_3001).

		Study 3 Open label, single-arm, intro-patient controlled study to evaluate the long-term safety and efficacy of garadacimab when administered as a prophylaxis in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE), (CSL312_3002). **Study 4** Open label, intra-patient controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of garadacimab when administered as a prophylaxis in children from 2 to less than 12 years of age with hereditary angioedema (HAE).
Extrapolation, modelling and simulation studies	2	**Study 5** Population pharmacokinetic modelling and analyses to describe the pharmacokinetics of garadacimab in adolescent patients from 12 to less than 18 years of age and adults with hereditary angioedema. **Study 6** Analysis of existing in-house exposure data to supporting the extrapolation of PK/renal clearance from adult and adolescent subjects to paediatric subjects from 2 to less than 12 years of age with hereditary angioedema and inform dose selection for paediatric subjects from 2 to less than 12 years of age.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes